- Cat.Number : AS-29907-01
- Manufacturer Ref. :
This is one of the predominant amyloid peptide structures deposited in human brain of Alzheimer’s disease and Down’s syndrome patients. N-terminally truncated pyroglutamate-modified beta-Amyloid forms such as Aß(3-42) and Aß (11- 42) have been described as major compounds in the senile plaques. Pyro-Glu modified beta-Amyloid forms are more resistant to degradation, show higher toxicity and have increased aggregation propensity compared to non-modified beta-Amyloid.
|Sequence one letter code||
|Sequence three letter code||
|CAS registry number||
|Molecular Mass/ Weight||
|Quantity & Purity|
|Storage & stability|
|Sub-category Research Area|
|Source / Species||
You may also be interested in the following product(s)
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases
J Neural Transm . 2010 Jan 01 ; 117(1) 85 | DOI : 10.1007/s00702-009-0314-x
- O. Wirths
N‐terminal truncated pyroglutamyl β amyloid peptide Aβpy3‐42 shows a faster aggregation kinetics than the full‐length Aβ1‐42.
Biopolymers . 2009 Oct 01 ; 91(10) 861 | DOI : 10.1002/bip.21271
- C. D'Arrigo
Effect on memory of acute administration of naturally secreted fibrils and synthetic amyloid-beta peptides in an invertebrate model.
Neurobiol Learn Mem . 2007 Oct 24 ; 89(4) 407 | DOI : 10.1016/j.nlm.2007.08.011
- M. Feld
β-Amyloid is different in normal aging and in Alzheimer disease.
J. Biol. Chem. . 2015 Aug 15 ; 280(40) 34186 | DOI : 10.1074/jbc.M501694200
- A. Piccini
Presenilin-1 mutations in Alzheimer's disease
Neurobiol Nature . 2000 Jun 01 ; 405 531 | DOI : https://doi.org/10.1038/35014735
- C. Russo
- et al